美国政府宣布美英就药品定价达成原则性协议

Core Points - The U.S. and U.K. have reached a principled agreement on drug pricing, as announced by the U.S. Trade Representative's Office [1] - The agreement mandates that the U.K. National Health Service (NHS) will increase the net price of new drugs by 25% [1] - The agreement ensures continued investment from U.K. pharmaceutical companies in the U.S. [1] - The U.S. has agreed to exempt drugs, drug ingredients, and medical technologies originating from the U.K. from Section 232 tariffs [1] - During the Trump administration, the U.S. will not initiate a "301 investigation" into the U.K.'s drug pricing practices [1]